Gerresheimer stock holds at EUR27 in tight trading range

Gerresheimer AG (ISIN DE000A0LD6E6) stock is quoted at EUR27.40 on Tradegate as of August 21, 2026, giving the specialist in pharmaceutical and cosmetic packaging a market capitalization of EUR2.545 billion based on current market data. Recent quote snapshots for August 20-21, 2026 show the shares changing hands between EUR27.36 and EUR27.68, keeping Gerresheimer stock anchored in a narrow band just below the EUR30 level.

Stock trades in a narrow band

Recent quote overviews indicate that Gerresheimer shares traded between EUR27.36 and EUR27.68 around August 20, 2026, illustrating a tight intraday range of EUR0.32 during that period. With the stock at EUR27.40 as of August 21, 2026, the price sits within that band and remains below the psychologically important EUR30 mark, underlining the mid-cap character of the equity within European healthcare and industrial packaging.

Based on a share price of EUR27.40 and an equity market capitalization of EUR2.545 billion as of August 21, 2026, Gerresheimer commands a valuation that positions it firmly in the European mid-cap segment. The stock’s consolidation below EUR30 suggests that investors are waiting for the next set of earnings figures or guidance updates before reassessing the valuation, particularly given the company’s exposure to higher value-added pharmaceutical and cosmetic packaging solutions.

Recent fundamentals and valuation context

Current day-filtered market-data snapshots emphasize Gerresheimer’s role as a specialist in healthcare packaging and medical technology, but do not restate the exact revenue and earnings figures for the most recent quarter or fiscal year. In this context, the visible focus in recent coverage is on segment trends rather than precise headline numbers, highlighting that growth in recent periods has been concentrated in more sophisticated packaging formats and medical technology products instead of commodity glass containers.

Historically, Gerresheimer’s financial reports have shown that the company’s revenue mix has shifted toward higher-margin pharmaceutical primary packaging and cosmetic solutions, which tend to support more resilient profitability than traditional standard containers. While the latest quarter’s revenue and earnings metrics are not restated in the current day-filtered overview, the emphasis on these segments indicates that recent operational performance has likely been driven by demand from the global pharmaceuticals industry and branded cosmetic manufacturers.

For valuation purposes, the combination of a EUR27.40 share price and a EUR2.545 billion market capitalization as of August 21, 2026 places Gerresheimer within a peer group of European mid-cap healthcare packaging firms. Investors often compare such companies on metrics like price-to-earnings ratios, enterprise value-to-EBITDA, and free cash flow yield, although the current market-data snapshots do not specify those ratios for Gerresheimer explicitly. The observed trading range below EUR30 nevertheless reflects a market view that balances growth prospects in specialized packaging against cyclical exposure in more commoditized segments.

Packaging and medical technology as core business

Gerresheimer’s core business spans pharmaceutical packaging, cosmetic containers, and medical technology solutions designed to ensure product safety, patient convenience, and brand differentiation. The company supplies glass and plastic vials, syringes, ampoules, and inhaler components to drug manufacturers, along with high-quality bottles and jars to cosmetic companies that demand reliable, aesthetically appealing packaging for their products.

In the medical technology arena, Gerresheimer develops device components such as inhalers, injection systems, and diagnostic housings that integrate with broader treatment and monitoring systems. These products typically carry stricter regulatory requirements and higher technical complexity than standard packaging, supporting a more attractive margin profile when scaled across global healthcare markets. As pharmaceutical and biotechnology companies continue to invest in innovative therapies that require precise dosing and secure delivery, demand for such specialized packaging and device solutions forms a structural support for Gerresheimer’s underlying business.

Shares priced below EUR30

With Gerresheimer stock quoted at EUR27.40 on Tradegate as of August 21, 2026 in euros, the price remains below the EUR30 threshold that many chart observers use as a reference level for the shares. The mid-cap valuation of EUR2.545 billion at that price level reflects the market’s current assessment of Gerresheimer’s position in healthcare packaging and medical technology, pending the next formally reported earnings data point.

Go deeper

Read-more coverage on Gerresheimer stock can provide additional color on segment performance, geographic revenue mix, and margin trends once the latest quarterly or annual figures are fully incorporated into market analytics. Such context helps clarify how the company’s emphasis on higher value-added pharmaceutical and cosmetic packaging is influencing its long-term growth and profitability profile.

Investor Relations

Further details on Gerresheimer’s investor communications, including upcoming reporting dates and strategic updates, are typically available via the company’s own investor relations channels and regulatory filings, where management outlines operational priorities, capital allocation, and expansion plans.

Pharmaceutical and cosmetic packaging

Gerresheimer’s representative product area is pharmaceutical and cosmetic packaging, where the company offers glass and plastic solutions tailored to the needs of global drug makers and beauty brands. Standardized vials and ampoules provide robust containment for injectable medicines, while specialized bottles and jars deliver the visual and tactile qualities sought by cosmetic customers. By combining precise manufacturing processes with design flexibility, Gerresheimer supports both regulatory compliance and brand differentiation across its packaging portfolio.

Current stock level

Gerresheimer stock is quoted at EUR27.40 on Tradegate as of August 21, 2026, with the shares denominated in euros and traded primarily on German exchanges such as Xetra. At this level, the stock reflects a mid-cap valuation profile and remains in the tight trading range observed around the EUR27-28 band in recent sessions, leaving room for the next corporate update to shape investor sentiment.

Fact box

Company: Gerresheimer AG
ISIN: DE000A0LD6E6
Ticker: GXI
Exchange: Xetra (Germany)
Price (as of August 21, 2026, 1:30 a.m. ET): EUR27.40
Market cap: EUR2.545 billion (as of August 21, 2026)
Sector / Industry: Healthcare packaging and medical technology
Index membership: European mid-cap segment